EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
[HTML][HTML] Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases
A Bodaghi, N Fattahi, A Ramazani - Heliyon, 2023 - cell.com
The use of biomarkers as early warning systems in the evaluation of disease risk has
increased markedly in the last decade. Biomarkers are indicators of typical biological …
increased markedly in the last decade. Biomarkers are indicators of typical biological …
Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management
JA Eastham, GB Auffenberg, DA Barocas… - The Journal of …, 2022 - auajournals.org
Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …
A systematic review of the evidence for the decipher genomic classifier in prostate cancer
Context Molecular biomarkers aim to address the established limitations of clinicopathologic
factors to accurately risk stratify patients with prostate cancer (PCa). Questions remain as to …
factors to accurately risk stratify patients with prostate cancer (PCa). Questions remain as to …
Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update
PURPOSE Update all preceding ASCO guidelines on initial hormonal management of
noncastrate advanced, recurrent, or metastatic prostate cancer. METHODS The Expert …
noncastrate advanced, recurrent, or metastatic prostate cancer. METHODS The Expert …
Can negative prostate-specific membrane antigen positron emission tomography/computed tomography avoid the need for pelvic lymph node dissection in newly …
Context The role of positron emission tomography/computed tomography (PET/CT) with
prostate-specific membrane antigen (PSMA) in the primary staging for patients with prostate …
prostate-specific membrane antigen (PSMA) in the primary staging for patients with prostate …
[HTML][HTML] Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
[HTML][HTML] Complexities of prostate cancer
Prostate cancer has a long disease history and a wide variety and uncertainty in individual
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …
Harm-to-benefit of three decades of prostate cancer screening in Black men
Background Prostate-specific antigen screening has profoundly affected the epidemiology of
prostate cancer in the United States. Persistent racial disparities in outcomes for Black men …
prostate cancer in the United States. Persistent racial disparities in outcomes for Black men …
[HTML][HTML] Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer
Context Genomic stratification can impact prostate cancer (PC) care through diagnostic,
prognostic, and predictive biomarkers that aid in clinical decision-making. The temporal and …
prognostic, and predictive biomarkers that aid in clinical decision-making. The temporal and …